 Abstract germ cell tumours, GCTs, are rare types of cancer that affect infants, children, adolescents and adults. They are divided into two categories based on their developmental stage, pre-pubescent, type 1, and post-pubescent, type 2. Type 1 GCTs are limited to benign teratomas and malignant yolk sac tumours, YST, while type 2 GCTs include seminomas and non-seminomas. Genomic analyses of GCTs in children and adolescents revealed that the WNT pathway is activated by mutations, copy number alterations and differential promoter methylation. This activation leads to poor clinical outcomes and suggests that WNT inhibition could be used to treat GCTs. Additionally, small molecule WNT inhibitors were found to suppress GCT cells both in vitro and in vivo, providing a potential therapeutic option for treating this type of cancer. This article was authored by Lin Xu, Joshua L. Pierce, Angelica Sanchez and others.